ABOS · Acumen Pharmaceuticals, Inc. · Debt
$1.98
-0.08 (-3.88%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$143.19M
Shares
72.32M
Volume · Oct 23
541.79K
Avg daily vol (3M)
458.35K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 11,896,000 | 10-Q filed 2026-08-12 |
| Operating lease liabilities | 2026-06-30 | USD 77,000 | 10-Q filed 2026-08-12 |
| Short-term borrowings | 2026-06-30 | USD 19,673,000 | 10-Q filed 2026-08-12 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.